

产品名称: Leukadherin 1

产品别名: Leukadherin-1

生物活性:

Description	Leukadherin-1 is a specific agonist of CR3 and the leukocyte surface integrin CD11b/CD18.				
In Vitro	Leukadherin-1 (LA1) modulates natural killer (NK) cell inflammatory cytokine secretion. The SLE-associated CD11b-R77H variant does not influence NK cell response to Leukadherin-1. Leukadherin-1 does not modulate Syk activation in NK cells. Leukadherin-1 (LA1) does not modulate signal transducer and activator of transcription (STAT)-4 phosphorylation. Leukadherin-1 modulates TLR-2 and TLR-7/8-induced monocyte cytokine secretion[1].				
In Vivo	Leukadherin-1 decreases macrophage infiltration in the lungs during hyperoxia. Furthermore, treatment with Leukadherin-1 improves alveolarization and angiogenesis and decreases pulmonary vascular remodeling and PH. Targeting leukocyte trafficking using Leukadherin-1, an integrin agonist, is beneficial in preventing lung inflammation and protecting alveolar and vascular structures during hyperoxia[2].				
Solvent&Solubility	In Vitro: DMSO : 6 mg/mL (14.24 mM; Need ultrasonic)				
	<div>Preparing Stock Solutions</div>	<div>SolventMassConcentration</div>	1 mg	5 mg	10 mg
		1 mM	2.3725 mL	11.8627 mL	23.7254 mL
		5 mM	0.4745 mL	2.3725 mL	4.7451 mL
		10 mM	0.2373 mL	1.1863 mL	2.3725 mL
<div>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</div> <div>储备液的保存方式和期限：-80℃，6 months；-20℃，1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。</div>					
References	<div>[1]. Roberts AL, et al. The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling. Clin Exp Immunol. 2016 Sep;185(3):361-71.</div> <div>[2]. Jagarapu J, et al. Efficacy of Leukadherin-1 in the Prevention of Hyperoxia-Induced Lung Injury in Neonatal Rats. Am J Respir Cell Mol Biol. 2015 Dec;53(6):793-801.</div>				
实验参考:					
Cell Assay	Supernatant cytokines are quantified after stimulation and culture for 18 h (monocytes) or 24 h (NK cells). Except for bead-based stimulation, all experiments are conducted using 100 μL cells in a 96-well plate format. NK cell stimuli are added as follows: (1) Syk inhibitor (1 μM), (2) Leukadherin-1 or dimethylsulphoxide (DMSO) (vector control) (7.5 μM). Shown to induce 82% of maximum response with negligible off-target effect, (3) anti-CD210 or isotype control (5 μg/mL), (4) 30-45 min after Leukadherin-1 NK cells are stimulated with combinations of IL-12 (10 ng/mL), IL-15 (30 ng/mL) or IL-18 (10 ng/mL): either IL-12 + IL-15 or IL-12 + IL-18. Monocytes are stimulated using pam3csk4 (TLR-2 agonist, 300 ng/mL) or R848 (TLR-7/8 agonist, 2 μg/mL). Supernatants are stored at -80℃ for < 1 month before quantification. To exclude non-specific Leukadherin-1-mediated cytotoxicity, the cell viability is assayed at 24 h using the CellTitre-Glo reagent. No significant loss of viability in comparison with the DMSO control is seen, concurring with published data in other cell types. [1]				
	[1]. Roberts AL, et al. The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1				

References	<p><u>suppresses human innate inflammatory signalling. Clin Exp Immunol. 2016 Sep;185(3):361-71.</u></p> <p>[2]. <u>Jagarapu J, et al. Efficacy of Leukadherin-1 in the Prevention of Hyperoxia-Induced Lung Injury in Neonatal Rats. Am J Respir Cell Mol Biol. 2015 Dec;53(6):793-801.</u></p>
-------------------	--



源叶生物